Details for New Drug Application (NDA): 219282
✉ Email this page to a colleague
NDA 219282 describes GRANISETRON HYDROCHLORIDE, which is a drug marketed by Am Regent, Amneal, Baxter Hlthcare Corp, Bionpharma, Dr Reddys, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Hikma, Hikma Farmaceutica, Mylan Asi, Pharmobedient, Rising, Sandoz, Sandoz Inc, Teva Pharms Usa, Wockhardt Usa, Yung Shin Pharm, Intra Sana Labs, Apotex Inc, Aurobindo Pharma Usa, Barr, Chartwell Molecular, Dr Reddys Labs Ltd, Natco Pharma, Orbion Pharms, Taro, and Teva Pharms, and is included in forty-seven NDAs. It is available from seven suppliers. Additional details are available on the GRANISETRON HYDROCHLORIDE profile page.
The generic ingredient in GRANISETRON HYDROCHLORIDE is granisetron hydrochloride. There is one drug master file entry for this compound. Eight suppliers are listed for this compound. Additional details are available on the granisetron hydrochloride profile page.
The generic ingredient in GRANISETRON HYDROCHLORIDE is granisetron hydrochloride. There is one drug master file entry for this compound. Eight suppliers are listed for this compound. Additional details are available on the granisetron hydrochloride profile page.
Summary for 219282
| Tradename: | GRANISETRON HYDROCHLORIDE |
| Applicant: | Intra Sana Labs |
| Ingredient: | granisetron hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 219282
| Mechanism of Action | Serotonin 3 Receptor Antagonists |
Suppliers and Packaging for NDA: 219282
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| GRANISETRON HYDROCHLORIDE | granisetron hydrochloride | SOLUTION;ORAL | 219282 | ANDA | Intra-Sana Laboratories | 80056-801 | 80056-801-30 | 30 mL in 1 BOTTLE, GLASS (80056-801-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | EQ 2MG BASE/10ML | ||||
| Approval Date: | Mar 17, 2025 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
